Cargando…

PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH

Treatment with immune checkpoint inhibitors (ICI) such as carrizumab leads to immune-mediated adverse effects including severe acute graft versus host disease (aGVHD) and secondary hemophagocytic syndrome (sHLH). Herein, we present two cases where aGVHD and sHLH developed after ICI administration, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Zhi zhuo, Zhou, Mi, Ling, Jing, Cao, Lan, Kong, Lingjun, Cheng, Shengqin, Xiao, Peifang, Hu, Shaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800091/ https://www.ncbi.nlm.nih.gov/pubmed/36590870 http://dx.doi.org/10.1155/2022/1705905

Ejemplares similares

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

Interferon gamma (IFNg) production is associated to disease parameters in TLR9-induced secondary hemophagocytic lymphohistiocytosis (sHLH) in mice
por: De Min, Cristina, et al.
Publicado: (2014)

Case Report: Secondary Hemophagocytic Lymphohistiocytosis (sHLH) and Candida auris Fungemia in Post-acute COVID-19 Syndrome: A Clinical Challenge
por: Gautam, Sachin, et al.
Publicado: (2022)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD
por: Yao, Sun, et al.
Publicado: (2021)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

Oral Cancer in HSCT Pediatric Patients Arising on GVHD: A Comprehensive Review
por: Cantile, Tiziana, et al.
Publicado: (2022)

Early CD8(+)-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT
por: Ranti, Juha, et al.
Publicado: (2018)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

Successful Treatment of Relapsed Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report
por: Pi, Yubo, et al.
Publicado: (2022)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Cyclic adenosine monophosphate potentiates immune checkpoint blockade therapy in acute myeloid leukemia
por: Mao, Ping, et al.
Publicado: (2023)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
por: Gao, Junyan, et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
por: Kim, Ai-Ran, et al.
Publicado: (2011)

Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT
por: Luo, Rongmu, et al.
Publicado: (2022)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Kong, Jun, et al.
Publicado: (2022)

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
por: Rutella, Sergio, et al.
Publicado: (2022)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
por: Cerezo-Martin, J. M., et al.
Publicado: (2022)

Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T-cell responses in a murine acute myeloid leukemia model
por: Stroopinsky, Dina, et al.
Publicado: (2021)

Blood Stream Infection (BSI) and Acute Graft Versus Host Disease (GVHD) after Hematopoietic Stem Cell Transplantation (HSCT) are Associated
por: Poutsiaka, Debra D, et al.
Publicado: (2010)

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT
por: Copsel, Sabrina N., et al.
Publicado: (2019)

Early myeloid-derived suppressor cells (HLA-DR(−)/(low)CD33(+)CD16(−)) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT
por: Wang, Ke, et al.
Publicado: (2019)

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022)

Peptidomimetic blockade of MYB in acute myeloid leukemia
por: Ramaswamy, Kavitha, et al.
Publicado: (2018)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PB2299: UPDATE ON TRIAL IN PROGRESS: A PHASE 1B STUDY OF ELA026 IN PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH)
por: Patou, Gary, et al.
Publicado: (2023)

Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)—time to reappraise with modern diagnostic and treatment strategies?
por: Sandler, Robert David, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_no5d9p93i21m8d6l6smgdnjmj8